University of Ioannina
Association of established and novel risk factors with cardiovascular disease in patients with dyslipidemia
Abstract
dc:descriptionIntroduction: Despite available therapies used for cardiovascular (CV) prevention and their increased prescription rates during the last decade, cardiovascular disease (CVD) remains the leading mortality cause worldwide. There are limited data regarding CV and metabolic risk in dyslipidemic patients treated in the setting of CV prevention. Aims: To study CVD incidence in dyslipidemic patients taking multifactorial CV therapy and identify potential factors for residual CV and metabolic risk. Methods: This was a retrospective study including consecutive adult patients with dyslipidemia who attended the Outpatient Lipid Clinic of the University Hospital of Ioannina in Greece for ≥3 years (from 1999 to 2015). A complete assessment of their clinical and laboratory profile was performed at baseline visit, after 6 months and most recent visit. Concomitant therapies were recorded, with a particular emphasis on lipid-lowering drugs. We depicted the incidence of atherosclerotic cardiovascular disease (ASCVD) and identified possible risk factors. We evaluated and compared prognostic values of tools estimating the risk of ASCVD and atrial fibrillation (AF). We also evaluated whether an association between lipid parameters and ventricular repolarization indices (QTc interval, the Tpe interval, and the Tpe/QT ratio) exists. We captured the rates of proposed lipid, blood pressure (BP) and glycemic target attainment, along with rate of eligibility for treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. We assessed the correlations (r2) of apolipoprotein B (apoB) with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) according to the presence of high triglyceride (TG) levels, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). We recorded the rate of adverse effects related with lipid-lowering treatment and identified the corresponding risk factors. We assessed the overall effect of proton pump inhibitors (PPI) administration on LDL-C lowering and we investigated whether a statin escape phenomenon exists (as defined as an increase in low-density lipoprotein cholesterol (LDL-C) levels at the most recent visit by >10% compared with the value at 6 months following initiation of statin treatment). Also, we evaluated which factors were associated with incident chronic kidney disease (CKD) and hyponatremia in our study population. Results: A total of 1,334 subjects were included in the present study and followed-up for a median of 6 years (4-10). During follow-up, lipid-lowering therapy was prescribed to the majority of study participants (94%) with statins being the cornerstone therapy (91%), whereas 70% of those were on antihypertensive therapy. During 6-year follow-up, a total of 95 subjects (7%) were diagnosed with incident ASCVD (rate of ASCVD incidence: 10.4/1,000 patient-years). ASCVD incidence in our cohort was similar to that of a Hellenic cohort (ATTICA study) representative of the general population (10.4 vs 15.7/1,000 patient-years, respectively). T2DM (HR: 2.09, 95% CI: 1.18-3.70, p <0.001), previous ASCVD (HR: 2.04, 95% CI: 1.21-3.43, p <0.001), smoking (HR: 1.82, 95% CI: 1.17-2.84, p <0.001) and age (HR: 1.07, 95% CI: 1.04-1.09, p <0.001) were independent risk factors. ROC curve analysis indicated that CHADS2 and CHA2DS2-VASc scores have a strong predictive value for ASCVD (C-statistic: CHADS 0.592, p <0.01; CHA2DS2-VASc: 0.568, p <0.05). Nevertheless, they were not superior to SCORE and PCE risk score (C-statistic: 0.612, p <0.001 and 0.717, p <0.001, respectively). The correlation analysis (Spearman’s) failed to show any association between HDL-C or other lipid parameters and studied ECG parameters. Nevertheless, ROC curve analyses showed that both CHADS2 and CHA2DS2-VASc scores were significant predictors for new-onset AF (C-Statistic: CHADS2 0.679, p <0.001; CHA2DS2-VASc 0.698, p <0.001). After incorporating low HDL-C levels, both scores achieved slightly higher C-Statistic for AF prediction (0.690 and 0.707, respectively, p <0.001). According to the ESC/EAS 2019 guidelines, patients at very-high CV risk (n=391) exhibited the lowest rate of LDL-C target attainment compared with those at high (n=457), moderate (n=105) and low CV risk (n=47) (7 vs 12 vs 42 vs 70%, respectively, p <0.05) If subjects were on high-intensity statin plus ezetimibe, the corresponding rates would be 36, 47, 95 and 97% for the patients at very high, high, moderate and low CV risk, respectively. In case of additional treatment with PCSK9 inhibitors, the corresponding rates would be 69, 79, 100 and 100%, respectively. According to ACC/AHA 2018, 46% of patients with very high risk ASCVD and 31% of individuals with LDL-C ≥190 mg/dl both taking high-intensity statin therapy plus ezetimibe would be eligible for treatment with PCSK9 inhibitors. According to local Greek policy, the corresponding eligibility rate would be lower (22%) in patients with ASCVD, familial hypercholesterolemia (FH), DM with target organ damage or statin intolerance who were on maximally tolerated statin therapy with ezetimibe. Among elderly patients (≥65 years), LDL-C targets (ESC/EAS 2011), were attained by 27, 48 and 62% of those at very high, high and moderate risk, respectively. Of diabetic subjects, 71% had BP <140/85 mmHg, while 78% of non-diabetics had BP <140/90 mmHg. A higher proportion of non-diabetic individuals (86%) had BP <150/90 mmHg. Also, a higher proportion of diabetics had HbA1c <8% rather than <7% (88% and 47%, respectively). Of note, almost 1 out of 3 non-diabetic and 1 out of 10 diabetic individuals had achieved all 3 treatment targets. The correlations between apoB and LDL-C or non-HDL-C were similar for individuals with TGs <200 mg/dL. Although these correlations remained significant for individuals with high TG levels (≥200 mg/dL), the correlation factor was markedly decreased mostly in those with T2DM or MetS (r2=0.600, p <0.01, for the correlation between apoB and LDL-C; r2=0.604, p <0.01, for the correlation between apoB and non-HDL-C). In contrast, the corresponding correlations were stronger in non-diabetic/non-MetS dyslipidemic individuals (r2=0.710 and 0.714, respectively, p <0.01). The rates of liver ezymes and CK increase were 3% and 1%, whereas only 2% of study participants experienced myalgias. During follow-up ~12% of study participants developed T2DM. A higher risk of incident T2DM was observed in prediabetic individuals receiving high-intensity statin therapy compared with those on moderate-intensity (adjusted OR: 2.12, 95% CI: 1.06-4.24, p <0.05) and those not taking a statin (adjusted OR: 4.90, 95% CI: 1.16-20.66, p <0.05). The addition of ezetimibe to statin treatment did not increase the risk of incident T2DM in prediabetic individuals (adjusted OR: 0.89, 95% CI: 0.36-2.22, p >0.05). An additional analysis showed that among prediabetic subjects, atherogenic dyslipidemia increased T2DM risk (adjusted OR: 3.44, 95% CI: 1.31-9.04, p=0.01). The same was true for overweight/obese status (adjusted OR: 5.60, 95% CI: 2.19-14.30, p <0.01). There was no significant difference regarding T2DM risk between metabolically healthy non-obese (MHNO) and metabolically healthy obese (MHO) subjects (adjusted OR: 1.46, 95% CI: 0.76-2.82, p >0.05). Metabolically unhealthy obese (MUO) patients had greater T2DM risk than MHNO (adjusted OR: 7.87, 95% CI: 4.02-15.42, p <0.01), MHO (adjusted OR: 5.45, 95% CI: 2.47-12.04, p <0.01) and metabolically unhealthy non-obese (MUNO) subjects (adjusted OR: 2.68, 95% CI: 1.28-5.64, p <0.01). Subjects receiving statin + PPI had a higher LDL-C reduction by 6.4% compared with those taking a statin alone (fully adjusted p <0.01), whereas 31% of 181 eligible subjects exhibited the statin escape phenomenon. During follow-up (6 years; IQR:4-10), 11.9% of subjects developed CKD, whereas the median annual eGFR decline was 0.69 mL/min/1.73 m2 (IQR: 0.45-2.33). Multivariate analysis showed that baseline uric acid levels (HR: 1.26, 95% CI: 1.09-1.45, p=0.001), female sex (HR: 1.74, 95% CI: 1.14-2.65, p=0.01), age (HR: 1.10, 95% CI: 1.07-1.12, p <0.001), T2DM (HR: 1.67, 95% CI: 1.05-2.65, p <0.05), ASCVD (HR: 1.62, 95% CI: 1.02-2.58, p <0.05), decreased baseline renal function (eGFR <90 mL/min/1.73 m2) (HR: 2.38, 95% CI: 1.14-4.81, p <0.05) and LDL-C reduction (HR: 0.995, 95% CI: 0.991-0.998, p=0.01) were associated with incident CKD. High HDL-C levels were associated with risk of hyponatremia (adjusted HR: 1.02, 95% CI: 1.01-1.04, p <0.01). Conclusions: 1. We showed that CVD incidence in high risk dyslipidemic subjects intensively treated was similar to a Hellenic cohort at lower CV risk.2. We investigated which CV risk factors are associated with new ASCVD events in high risk patients intensively treated in the setting a tertiary lipid clinic. DM, history of previous ASCVD, smoking and age were independent factors for ASCVD risk in dyslipidemic subjects on multifactorial cardiovascular therapy. 3. We confirmed that CHADS2 and CHA2DS2-VASc scores exhibit a strong predictive value for incident ASCVD in dyslipidemic individuals without AF, without being superior to SCORE and PCE. 4. Although no association was found between HDL-C and ventricular repolarization indexes, our study was the first to show that CHADS2 and CHA2DS2-VASc scores predict incident AF among dyslipidemic patients, with modest further improvement of performance when low HDL-C levels are included. 5.Even in the setting of a lipid clinic, we confirmed previous data reporting that the majority of patients and especially those at high CV risk, such as those with ASCVD or FH, remain sub-optimally treated in everyday clinical practice. 6. We underlined the imperative need for combination therapies of most potent statins with ezetimibe ± PCSK9 inhibitors to achieve optimal LDL-C levels in clinical practice. In addition, we confirmed that a considerable proportion of patients with ASCVD or FH are eligibile for treatment with PCSK9 inhibitors. 7. We were the first to assess the correlations of apoB with LDL-C and non-HDL-C on the basis of the presense of MetS or DM in combination with TG stratification. In this setting, our study showed that apoB correlation with both LDL-C and non-HDL-C is reduced in individuals with high TG levels and mostly in those with DM or MetS. 8. We confirmed previous evidence arguing that rates of adverse effects caused by statin therapy are actually low in clinical practice, whereas a neutral effect, if not favorable, on renal function was noticed. 9. We underlined that high-intensity statin therapy is associated with a higher risk of incident DM in prediabetic individuals compared with previous results derived from randomized controlled trials. Moreover, we confirmed that ezetimibe has a neutral effect on glucose metabolism. 10. We were the first to demonstrate that atherogenic dyslipidemia increases T2DM risk in statin-treated patients, while its combination with IFG and overweight/obesity dramatically increases the diabetogenic impact of statin therapy. These results could help physicians tailor therapeutic strategies minimizing DM risk before initiating statin therapy. 11. We were the first to show that metabolically healthy obesity does not seem to significantly increase T2DM risk in statin-treated individuals in contrast to metabolically unhealthy non-obesity and especially metabolically unhealthy obesity. Thus, the risk of statin-associated new-onset T2DM may depend mainly on the metabolic rather than obesity status. 12. We confirmed limited evidence arguing for the existence of statin escape phenomenon in clinical practice, although its clinical significance remains uncertain. In this context, patients with larger than anticipated LDL-C reduction should be carefully monitored. 13. We were the first to show a potential interaction between PPIs and statins, that is chronic PPI use may be associated with a modest enhancement in LDL-C lowering efficacy of statins. 14. We confirmed that hyperuricemia increases CKD risk in dyslipidemic individuals treated with statins and reno-protective antihypertensive drugs. 15.We confirmed limited evidence arguing that high HDL-C levels are associated with hyponatremia in dyslipidemic individuals.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Barkas, Fotios
- Μπάρκας, Φώτιος
Subjects
dc:subject × 14Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/48019